---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000028"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:11:08.128229+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibrx promotes David Matly to President; CSO Eckelman resigns

## Summary
- David J. Matly appointed President effective April 1, 2025, adding to his role as EVP, Chief Commercial and Business Development Officer.
- Mark Lappe remains CEO and Chair but no longer holds President title; Matly's base salary increased to $601,670.
- Matly granted 50,000 stock options vesting over four years under the company's equity plan.
- Brendan P. Eckelman resigned as EVP, Chief Scientific Officer effective March 31, 2025, to found a new private biotech.
- Company accelerated vesting of 50,000 of Eckelman's outstanding options and extended post-termination exercise period to October 1, 2026.

## SEC filing metadata
- accession: 0002007919-25-000028
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/0002007919-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/inhibrx-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000028
- JSON: https://secwatch.observer/filing/0002007919-25-000028.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000028.txt

## Key facts
- Executive change
  Mark Lappe changed role as Chief Executive Officer and Chairperson of the Board at Inhibrx Biosciences, Inc..
  - Action: relinquished President title
  - Role: Chief Executive Officer and Chairperson of the Board
  source text: Mark Lappe will continue in his roles as Chief Executive Officer and Chairperson of the Board of Directors, but will no longer hold the title of President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/0002007919-25-000028-index.htm
- Executive change
  David J. Matly was appointed as President at Inhibrx Biosciences, Inc..
  - Action: appointed
  - Role: President
  source text: On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/0002007919-25-000028-index.htm
- Executive change
  Brendan P. Eckelman resigned as EVP, Chief Scientific Officer at Inhibrx Biosciences, Inc..
  - Action: resigned
  - Role: EVP, Chief Scientific Officer
  source text: On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000028/0002007919-25-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.